|
审核状态: Project audit state: |
通过审核 Successful |
|
注册号: Registration number: |
ChiCTR-TRC-12002379 |
|
最近更新日期: Date of Last Refreshed on: |
2015-05-03 11:38:48 |
|
注册时间: Date of Registration: |
2012-07-25 00:00:00 |
|
注册号状态: |
补注册 |
|
Registration Status: |
Retrospective registration |
|
注册题目: |
不同方案治疗早期高原肺水肿的多中心、随机、单盲、平行阳性药物对照临床试验 |
|
Public title: |
A Multicenter Random Single Blind Parallelism Drugs Contrast Eeperiment of Treatment of Pristine HAPE with Diffrent Projects |
|
注册题目简写: |
|
|
English Acronym: |
|
|
研究课题的正式科学名称: |
急进高原人群急性高原病预警、早期诊断及其规范化防治研究 |
|
Scientific title: |
Precaution, prophase diagnose and standard treatment study of rapid get onto plateau personnel acute altitude disease |
|
研究课题代号(代码): Study subject ID: |
|
|
在二级注册机构或其它机构的注册号: The registration number of the Partner Registry or other register: |
|
申请注册联系人: |
胡明冬 |
研究负责人: |
徐剑铖 |
|
Applicant: |
Mingdong Hu |
Study leader: |
Jancheng Xu |
|
申请注册联系人电话: Applicant telephone: |
+86 13500362524 |
研究负责人电话:
Study leader's |
+86 13708320902 |
|
申请注册联系人传真 : Applicant Fax: |
研究负责人传真: Study leader's fax: |
||
|
申请注册联系人电子邮件: Applicant E-mail: |
huhanshandd@yahoo.com.cn |
研究负责人电子邮件: Study leader's E-mail: |
xu822036@sohu.com |
|
申请单位网址(自愿提供): Applicant website(voluntary supply): |
研究负责人网址(自愿提供): Study leader's website(voluntary supply): |
||
|
申请注册联系人通讯地址: |
第三军医大学第二附属医院呼吸内科 |
研究负责人通讯地址: |
第三军医大学第二附属医院呼吸内科 |
|
Applicant address: |
Respiratory department of the second affiliated hospital of the third military medical university |
Study leader's address: |
Respiratory department of the second affiliated hospital of the third military medical university |
|
申请注册联系人邮政编码: Applicant postcode: |
研究负责人邮政编码: Study leader's postcode: |
||
|
申请人所在单位: |
第三军医大学第二附属医院 |
||
|
Applicant's institution: |
the second affiliated hospital of the third military medical university |
||
|
研究负责人所在单位: |
|
||
|
Affiliation of the Leader: |
|
||
|
是否获伦理委员会批准: |
是 |
||
|
Approved by ethic committee: |
Yes |
||
|
伦理委员会批件文号: Approved No. of ethic committee: |
(2012)临审(2012018) |
伦理委员会批件附件: Approved file of Ethical Committee: |
|
|
批准本研究的伦理委员会名称: |
第三军医大学第二附属医院医学伦理委员会 |
||
|
Name of the ethic committee: |
Ethics committee of the second affiliated hospital of the third military medical university |
||
|
伦理委员会批准日期: Date of approved by ethic committee: |
2012-05-09 00:00:00 | ||
|
伦理委员会联系人: |
|
||
|
Contact Name of the ethic committee: |
|
||
|
伦理委员会联系地址: |
|
||
|
Contact Address of the ethic committee: |
|
||
|
伦理委员会联系人电话: Contact phone of the ethic committee: |
伦理委员会联系人邮箱: Contact email of the ethic committee: |
||
|
研究实施负责(组长)单位: |
第三军医大学第二附属医院 |
||||||||||||||||||||||
|
Primary sponsor: |
The second affiliated hospital of the third military medical university |
||||||||||||||||||||||
|
研究实施负责(组长)单位地址: |
第三军医大学第二附属医院心血管内科 |
||||||||||||||||||||||
|
Primary sponsor's address: |
Vasculocardiology deparment of the second affiliated hospital of the third military medical university |
||||||||||||||||||||||
|
试验主办单位(项目批准或申办者): Secondary sponsor: |
|
||||||||||||||||||||||
|
经费或物资来源: |
卫生部行业专项 |
||||||||||||||||||||||
|
Source(s) of funding: |
National Ministry of health industry special subject |
||||||||||||||||||||||
|
研究疾病: |
急性高原病 |
||||||||||||||||||||||
|
Target disease: |
acute altitude disease |
||||||||||||||||||||||
|
研究疾病代码: |
|
||||||||||||||||||||||
|
Target disease code: |
|
||||||||||||||||||||||
|
研究类型: |
干预性研究 |
||||||||||||||||||||||
|
Study type: |
Interventional study |
||||||||||||||||||||||
|
研究所处阶段: |
上市后药物 | ||||||||||||||||||||||
|
Study phase: |
4 |
||||||||||||||||||||||
|
研究设计: |
随机平行对照 |
||||||||||||||||||||||
|
Study design: |
Parallel |
||||||||||||||||||||||
|
研究目的: |
把通过系统评价(META分析)初步筛选出的三种早期高原肺水肿药物治疗方案随机用于早期高原肺水肿患者的治疗,以期筛选出最优化治疗方案,评价其实际临床应用效果。 |
||||||||||||||||||||||
|
Objectives of Study: |
Drug treatment programs through systematic reviews (META analysis) initial screening of the three early high altitude pulmonary edema were used for the early treatment of patients with high pristine altitude pulmonary edema, in order to filter out the optimal treatment program, to evaluate the actual clinical application effect. |
||||||||||||||||||||||
|
药物成份或治疗方案详述: |
氨茶碱、地塞米松和硝苯地平 |
||||||||||||||||||||||
|
Description for medicine or protocol of treatment in detail: |
Aminophylline, dexamethasone, and nifedipine |
||||||||||||||||||||||
|
纳入标准: |
①年龄18~60岁; |
||||||||||||||||||||||
|
Inclusion criteria |
①18 to 60 years of age;②Patient of achieved the diagnostic criteria of early HAPE Agreement; ③Patients signed the informed consent. |
||||||||||||||||||||||
|
排除标准: |
①有严重心、脑、肝、肾等其他严重疾病; |
||||||||||||||||||||||
|
Exclusion criteria: |
Severe heart, brain, liver, kidney and other serious diseases; |
||||||||||||||||||||||
|
研究实施时间: Study execute time: |
从 From 2011-06-07 00:00:00至 To 2013-04-29 00:00:00 |
征募观察对象时间: Recruiting time: |
从 From 2011-06-07 00:00:00 至 To 2013-04-29 00:00:00 |
|
干预措施: Interventions: |
|
|
研究实施地点: Countries of recruitment and research settings: |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
测量指标: Outcomes: |
|
|
采集人体标本:
Collecting sample(s)
|
|
|
征募研究对象情况: Recruiting status: |
正在进行 Recruiting |
年龄范围: Participant age: |
|
||||||
|
性别: |
男女均可 |
Gender: |
Both |
||||||
|
随机方法(请说明由何人用什么方法产生随机序列): |
中心随机 |
||||||||
|
Randomization Procedure (please state who generates the random number sequence and by what method): |
central randomization |
||||||||
|
是否公开试验完成后的统计结果: Calculated Results after the Study Completed public access: |
公开/Public |
|
盲法: |
|
|
Blinding: |
|
|
试验完成后的统计结果(上传文件): |
|
|
Calculated Results after
|
|
|
是否共享原始数据: IPD sharing |
|
|
共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址): |
|
|
The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url): |
|
|
数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC: |
|
|
Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture: |
|
|
数据与安全监察委员会: Data and Safety Monitoring Committee: |